Morepen Laboratories Ltd., a leading Indian pharmaceutical company, has unveiled an ambitious expansion strategy to enhance its engagement with doctors, patients, pharmacies, and healthcare professionals nationwide. As part of this initiative, the company plans to strengthen its salesforce by adding over 1,000 medical representatives over the next three years, with more than 200 expected to come on board in FY26 alone.
This strategic move comes on the back of steady growth in Morepen’s formulations segment and aims to bolster its presence in the domestic market. The company is focused on aligning with India’s vision of accessible and affordable healthcare, while also expanding its footprint in both urban and rural areas.
“This marks a turning point for Morepen as we intensify our focus on the growing domestic finished dosage market,” said Mr. Sushil Suri, Chairman and Managing Director. “Backed by our leadership in high-value APIs, this expanded salesforce will help us gain a larger share of India’s ?2.38 lakh crore pharmaceutical market, improving margins and long-term stakeholder returns.”
Currently, Morepen’s formulations business generates around ?325 crore, and the company is targeting a ?1,000 crore turnover from finished dosages within five years. This will be driven by new, cost-effective products and deeper market penetration, supported by an aggressive expansion of its representative network.
With the Indian pharmaceutical market projected to touch $130 billion by 2030, growing at 8.2% annually, Morepen sees strong potential for growth. Its robust manufacturing capabilities and proven product portfolio position the company to meet the evolving demands of the Indian healthcare ecosystem while maintaining its double-digit growth trajectory.
Morepen continues to build on its reputation as India’s top exporter of six major APIs—including Loratadine, Montelukast, and Atorvastatin—earning investor trust through consistent financial performance, global quality benchmarks, and a forward-looking growth agenda.